SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs Q3 earnings report is the dominant focus, with traders debating whether a strong report and raised guidance can overcome elevated expectations amid a broader AI-stock pullback. Bulls point to continued AI growth, while bears warn that a beat may not be enough to prevent profit-taking or valuation pressure.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Attention centers on Zevras quarterly results and the pending CHMP re-examination of MIPLYFFA, with the FDAs follow-up on celiprolol also viewed as a potential catalyst. Traders see U.S. MIPLYFFA growth as a support, but debate whether European regulators will reverse their earlier negative opinion, while some express frustration with management and the stocks volatility.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Anticipation for QUILT-2.005 topline results on ANKTIVA plus BCG in BCG-naive bladder cancer dominates discussion, with traders debating whether the data will support broader first-line use after ANKTIVAs expanded bladder-cancer approval. Many are bullish on the potential commercial expansion and upcoming earnings, while others cite execution and competition concerns and blame short selling for recent weakness.

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Agenus Inc

Agenuss BOT+BAL immunotherapy data presented at ESMO, including early neoadjuvant colon cancer responses and sarcoma activity, are driving discussion. Bulls view the findings as promising validation, while skeptics point to small, nonrandomized studies and ongoing concerns about execution and dilution.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons quarterly results have focused attention on heavy AI infrastructure spending and its impact on cash flow, despite accelerating AWS growth that fell short of some investors expectations. Traders are split between worrying that the spending and financing burden may outweigh near-term returns and viewing the post-earnings selloff as an overreaction to strong cloud demand.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is caught in a semiconductor selloff as traders question whether hyperscalers massive AI spending will generate sufficient returns, with concerns about customer concentration and financing structures weighing on sentiment. Bulls counter that Anthropics filing and bank-backed financing for Broadcom equipment support future demand, while others see the deals guarantees as added risk.

ProShares Trust II - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

Traders are focused on SCO as a leveraged inverse-crude play, betting that oil could fall if Iran-related tensions ease and supply flows normalize, while others expect conflict and shipping disruptions to keep crude elevated. Many also complain that backwardation and daily-reset decay have caused SCO to lag oils declines, fueling debate over its tracking and suitability for longer holds.

Rubrik, Inc. engages in the provision of cloud data management solutions. Its solutions include backup and recovery, VM backup, Microsoft 365, ransom ware recovery, database backup, cloud solutions, and Polaris sonar. Rubrik products include data protection, data threat analytics, data security posture and cyber recovery. The company was founded by Bipul Sinha, Arvind Jain, Soham Mazumdar, and Arvind Nithrakashyap in December 2013 and is headquartered in Palo Alto, CA.

Rubrik Inc. - Ordinary Shares - Class A

Rubrik Inc. - Class A

Rubrik is under pressure after its latest earnings despite beating expectations and raising its outlook, as traders focus on slower cloud net-new ARR growth and cautious second-half guidance. Bulls view the pullback as profit-taking after a strong run and point to continued business growth, while skeptics argue high expectations and the guidance outlook warrant a lower valuation.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

A stronger-than-expected Q3 report and raised full-year outlook are supporting bullish attention, alongside Mercks Moderna-partnered melanoma vaccine meeting Phase 3 endpoints with Keytruda. Traders see potential oncology-platform value, but debate whether the results meet high expectations and how much upside the vaccine may add for Merck.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPaths sharp selloff following its earnings and Investor Day, alongside analyst downgrades and price-target cuts, is driving discussion; skeptics say growth and AI monetization still need to show up in results, while bulls see the companys agentic-AI orchestration strategy and cash position as undervalued.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioLineRx and Hemispherian Present Preclinical Data Demonstrating Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancer at ESMO 2026

BioLineRx and Hemispherian Present Preclinical Data Demonstrating Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancer at ESMO 2026 BioLineRx and Hemispherian Present Preclinical Data Demonstrating Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancer at ESMO 2026PR...

BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day

BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education DayPR NewswireTEL AVIV, Israel...

BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)

BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026) BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a...

BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update

BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update PR Newswire TEL AVIV, Israel, Aug. 31, 2026 - Second of five planned cohorts ongoing in Phase 1/2a trial of GLIX1 in GBM; third...

BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement

BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement PR Newswire TEL AVIV, Israel, Aug. 28, 2026 TEL AVIV, Israel, Aug. 28, 2026 /PRNewswire/ -- BioLineRx Ltd...

BioLineRx to Report Second Quarter 2026 Results on August 31, 2026

BioLineRx to Report Second Quarter 2026 Results on August 31, 2026 BioLineRx to Report Second Quarter 2026 Results on August 31, 2026 PR Newswire TEL AVIV, Israel, Aug. 25, 2026 Management to Hold Conference Call at 8:30 a.m. EDTTEL AVIV, Israel, Aug. 25, 2026 /PRNewswire/ -- BioLineRx Ltd...

BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026

BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026 BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO...

BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model

BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and...

BioLineRx (BLRX) Q1 2026 Earnings Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update

BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update PR Newswire TEL AVIV, Israel, May 27, 2026 - Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment of...

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.

Bioline Rx Ltd - ADR

BLRX Stock Surges Pre-Market On Cancer Trial Catalyst – Eyes 50-DMA Breakout For First Time In Nearly 2 Months

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>BioLineRx partnered with Hemispherian to conduct a trial testing GLIX1 in patients with Glioblastoma.</li><li>Early preclinical data showed strong anti-tumor activity, good brain penetration, and a favorable safety profile.</li><li>BioLineRx is currently testing Motixafortide in a Phase 2b trial for pancreatic cancer.</li></ul>Shares of BioLineRx Ltd. (BLRX) surged 10% in pre-market trading on Tuesday, putting the stock on track to test its 50-day moving average for the first time since early March, after the company hit a significant milestone by dosing the first patient in an early-stage trial of its new cancer therapy.BioLineRx has partnered with Hemispherian AS, a clinical-stage oncology firm, to conduct a trial testing GLIX1 in patients with Glioblastoma and other high-grade brain tumors.Meanwhile, retail sentiment for <a href="https://stocktwits.com/symbol/BLRX">BLRX</a> on Stocktwits remained in the ‘neutral’ territory over the past 24 hours.<h2 class="st-heading-2">Initial Trial Results Expected In 2027</h2>GLIX1 is a first-in-class oral therapy designed to selectively damage cancer cells by restoring TET2 activity, a tumor suppressor gene. This novel approach could provide a new treatment option for aggressive tumors such as Glioblastoma, where effective therapies remain limited, BioLineRx said.Early preclinical data showed strong anti-tumor activity, good brain penetration, and a favorable safety profile. The Phase 1 trial will enroll up to 30 patients to determine a safe dose, with initial results expected in the first half of 2027.“We believe GLIX1 has the potential to offer a novel therapeutic approach in this cancer indication, as well as in multiple other cancer indications, where DNA damage repair is critical for cancer survival,” said Philip Serlin, CEO of BioLineRx.<h2 class="st-heading-2">What Else Is In The Pipeline?</h2>BioLineRx is testing Motixafortide in a Phase 2b trial for pancreatic cancer, combining it with immunotherapy and standard chemotherapy. The study is progressing quickly, with an interim analysis expected later this year.The company is also testing Motixafortide for Sickle Cell Disease (SCD) and gene therapy. A Phase 1 study showed the drug can help mobilize stem cells for gene therapy in sickle cell disease.The stock has shed 22% of its value so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-glnd-stock-crash-to-52-week-low-today/cZB8sI8Re5A">Why Did GLND Stock Crash 30% In Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Artistic representation of a trending chart.

The biotech firm announced the dosing of its first patient in an early-stage trial of its new cancer therapy.

BioLineRx, Ltd.

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$BLRX Just a monthly PSA here, this company is a scam stock. There is no future to invest in. This is the hallmark of “Wolves of Wall Street.” There are countless stories of people betrayed and I for one will never let it go.

Feed

News

Sentiment

Earnings

Fundamentals

Info

BLRX BioLineRx, Ltd.

Fundamentals

Latest BLRX News